Nanoparticulate drug delivery for therapeutic applications

ChangeBridge: Patent Grants - Therapeutics (A61P)

Published April 7th, 2026

Detected April 7th, 2026

Summary

The USPTO granted Patent US12594347B2 to Duke University for compositions comprising self-assembling conjugates designed for nanoparticulate drug delivery. The patent covers conjugates with albumin binding domains and molecules having log D ≥ 1.5 at pH 7.4, intended for therapeutic applications including cancer treatment (A61P 35/00). Assignee: Duke University; Inventors: Parisa Yousefpour, Ashutosh Chilkoti.

View original document View source feed page

What changed

The USPTO granted Patent US12594347B2 to Duke University for a nanoparticulate drug delivery system comprising self-assembling conjugates with a polypeptide (transition temperature >50°C), an albumin binding domain, and a cysteine-linked molecule (log D ≥1.5). The patent contains 16 claims and covers compositions for therapeutic applications, including cancer treatment. The technology enables targeted drug delivery through temperature-sensitive self-assembly and albumin-mediated transport.

This is a routine patent grant notification and does not impose compliance obligations on third parties. Pharmaceutical companies and researchers developing drug delivery systems may wish to review the patent claims to assess potential licensing needs or design-around considerations. The patent provides Duke University with exclusive rights to the technology through the grant date.

Source document (simplified)

← USPTO Patent Grants

Nanoparticulate drug delivery systems

Grant US12594347B2 Kind: B2 Apr 07, 2026

Assignee

Duke University

Inventors

Parisa Yousefpour, Ashutosh Chilkoti

Abstract

Described herein are compositions that include an assembly of self-assembling conjugates. The self-assembling conjugates may include a polypeptide having a transition temperature (17) above 50° C. when the polypeptide is not attached to the conjugate, an albumin binding domain (ABD) attached to a first end of the polypeptide, and at least one molecule attached to a second end of the polypeptide through a cysteine group, wherein the molecule has an octanol-water distribution coefficient (log D) of greater than or equal to 1.5 at a pH of 7.4 when the molecule is not attached to the conjugate. Also described herein are methods of using the compositions.